Given that βARs influence adipose and muscle signaling differently across various pathological conditions, a deeper understanding of how βAR activation improves adipose and muscle function could help develop drugs that selectively target βAR signaling, potentially offering new treatment options for age‐related conditions like sarcopenia and metabolic diseases. This evidence concerns the gene ADRB2 and sarcopenia.